MilliporeSigma’s CRISPR Epigenetic Activator Named to The Scientist’s Top 10 Innovation List
- Award recognizes potential impact on human health
- Robust tool enables life science community to explore advanced regulatory aspects of gene expression
- Customizable for both targeted epigenetic manipulation and transcriptional regulation
St. Louis, Missouri, March 29, 2016 – The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and, today announced that The Scientist magazine has named the company’s CRISPR Epigenetic Activator one of its Top 10 Innovations of 2015.
The CRISPR Epigenetic Activator is a key product of the life science business after the acquisition of Sigma-Aldrich Corp. last year.
“The life science research community lacked an effective method for the activation of endogenous gene expression,” said Udit Batra, CEO of MilliporeSigma. “We are excited to bring the research community a highly specific, robust tool for both targeted epigenetic manipulation and transcriptional regulation.”
The annual Top 10 Innovations competition recognizes “the newest life science products making waves in labs and clinics,” according to an article in the December 2015 issue of The Scientist, which ranks the CRISPR Epigenetic Activator number six in a list of 10 innovations that could have a major impact on science and medicine.
The award recognizes the potential impact of the activator on human health by enabling new platforms for drug screening, gene therapy and disease monitoring.
The system will enable the life science community to explore advanced regulatory aspects of gene expression by allowing the epigenetic modification of genetic loci at both close and distal locations to a gene of interest.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.